Author: OurCrowd

[xAI in xAI] xAI Raises $20B Series E

Jan 6, 2026 |

xAI completed its upsized Series E funding round, exceeding the $15 billion targeted round size, and raised $20 billion. Investors participating in the round include Valor Equity Partners, Stepstone Group, Fidelity Management & Research Company, Qatar Investment Authority, MGX and Baron Capital Group, amongst other key partners. Strategic investors in the round include NVIDIA and Cisco Investments, who continue to support xAI in rapidly scaling our compute infrastructure and buildout of the largest GPU clusters in the world. Read...

Read More

[TechSee in PR Newswire] TechSee introduces integrated visual AI to Sophie Live, drastically improving complex service interactions

Jan 6, 2026 |

LAS VEGAS, Jan. 6, 2026 /PRNewswire/ — TechSee, a global leader in visual AI for customer service, today announced the availability of the enhanced Visual AI capabilities integrated into Sophie Live, an intelligent remote visual assistant designed to help service organizations resolve their most complex and costly customer issues. These capabilities are now part of the standard Sophie Live offering and available to all customers. Read...

Read More

[RO in PR Newswire] RO launches Wegovy® pill through integration with Novo Nordisk

Jan 5, 2026 |

NEW YORK, Jan. 5, 2026 /PRNewswire/ — Ro, the leading direct-to-patient healthcare company, announced today that it is working with Novo Nordisk on the nationwide launch of the new Wegovy® pill. Patients today can come to ro.co for the easiest way to access the first and only oral GLP-1 weight loss medication at the lowest available cash pay price. Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturer’s direct-to-patient expansion to date. Read more...

Read More

[DailyPay in PR Newswire] DailyPay Announces New $195 Million Senior Secured Revolving Credit Facility

Jan 5, 2026 |

NEW YORK, Jan. 5, 2026 /PRNewswire/ — DailyPay, the leading On-Demand Pay platform and financial wellness solution, today announced the closing on December 30, 2025 of a new $195 million senior secured revolving credit facility, further strengthening the company’s capital position and providing greater financial flexibility to support long term growth. Read...

Read More

[Alpha Tau in Alpha Tau] Alpha Tau submits first pre-market approval module to the FDA for Alpha DaRT® for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC)

Jan 5, 2026 |

Jerusalem, January 5, 2026 – Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”, or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced the submission of the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA), following the FDA’s previous decision to allow the Company to use the more flexible modular approach. Read...

Read More